Monday, May 25

Browsing: Letrozole

Survivors

TIP103 Randomized Phase 3 Clinical Trial Evaluating Atirmociclib Plus Letrozole Versus a CDK4/6 Inhibitor Plus Letrozole as First-Line Treatment for Patients With HR+/HER2− Advanced/Metastatic Breast Cancer

By NewsCancerMay 20, 20260

BackgroundCDK4/6 inhibitors, in combination with endocrine therapy, have improved survival outcomes when used as first-line treatment for patients with hormone…

Treatments

108 Long-Term Safety and Efficacy of First-Line Next Generation CDK4-Selective Inhibitor Atirmociclib + Letrozole for the Treatment of Patients With HR+/HER2− Metastatic Breast Cancer

By NewsCancerMay 17, 20260

BackgroundAtirmociclib (PF-07220060) is a highly selective and potent oral CDK4 inhibitor sparing other CDKs such as CDK6. We present long-term…

Support

Letrozole Monotherapy Doesn’t Demonstrate PFS Noninferiority in LGSOC

By NewsCancerApril 11, 20260

Compared with carboplatin/paclitaxel followed by letrozole, letrozole monotherapy failed to demonstrate noninferiority for progression-free survival (PFS) as initial treatment for…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Scientists discover hidden liver switch that cuts harmful cholesterol

Scientists supercharge natural killer cells to fight aggressive cancers

93 monarchE: Primary Overall Survival Results of Adjuvant Abemaciclib + Endocrine Therapy for HR+/HER2−, High-Risk, Early Breast Cancer

Browsing: Letrozole

TIP103 Randomized Phase 3 Clinical Trial Evaluating Atirmociclib Plus Letrozole Versus a CDK4/6 Inhibitor Plus Letrozole as First-Line Treatment for Patients With HR+/HER2− Advanced/Metastatic Breast Cancer

108 Long-Term Safety and Efficacy of First-Line Next Generation CDK4-Selective Inhibitor Atirmociclib + Letrozole for the Treatment of Patients With HR+/HER2− Metastatic Breast Cancer

Letrozole Monotherapy Doesn’t Demonstrate PFS Noninferiority in LGSOC

Scientists discover hidden liver switch that cuts harmful cholesterol

Scientists supercharge natural killer cells to fight aggressive cancers

93 monarchE: Primary Overall Survival Results of Adjuvant Abemaciclib + Endocrine Therapy for HR+/HER2−, High-Risk, Early Breast Cancer

94 Treatment Persistence and Dose Modifications in US Patients With HR+/HER2−, Node-Positive, Early Breast Cancer Treated With Adjuvant Abemaciclib

Scientists discover hidden liver switch that cuts harmful cholesterol

Scientists supercharge natural killer cells to fight aggressive cancers

93 monarchE: Primary Overall Survival Results of Adjuvant Abemaciclib + Endocrine Therapy for HR+/HER2−, High-Risk, Early Breast Cancer

94 Treatment Persistence and Dose Modifications in US Patients With HR+/HER2−, Node-Positive, Early Breast Cancer Treated With Adjuvant Abemaciclib

Latest Post

Scientists discover hidden liver switch that cuts harmful cholesterol

Scientists supercharge natural killer cells to fight aggressive cancers

93 monarchE: Primary Overall Survival Results of Adjuvant Abemaciclib + Endocrine Therapy for HR+/HER2−, High-Risk, Early Breast Cancer

Subscribe to Updates

What's Hot

Browsing: Letrozole